CancerSeq™ Plus Paraffin Tissue Tumor Sections: Stomach

BioChain's CancerSeq™ Plus FFPE tissues have undergone a preliminary screening process to detect copy number variations (CNVs), single nucleotide polymorphisms (SNPs), and insertions/deletions (indels) in key cancer gene regions. These tissues serve as an optimal resource for validating methodologies and pinpointing new variants within tumors.

The DNA isolated from FFPE tissues is then analyzed for mutations using Next Generation Sequencing (NGS) technology, specifically employing ArcherDx's VariantPlex system. This targeted enrichment system focuses on 67 cancer-associated genes. It employs innovative techniques such as random start sites and unique fragment identification to create intricate libraries for thorough analysis.